Navigation Links
Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments
Date:11/1/2007

priority, and we have made excellent progress through a combination of increased revenues, clinical development cost-sharing and spending controls."

THIRD QUARTER 2007 FINANCIAL RESULTS

For the quarter ended September 30, 2007, HGS reported increased revenues of $11.1 million, compared with revenues of $6.7 million for the same period in 2006. This included $7.8 million in revenue recognized from the Albuferon agreement with Novartis, and $1.6 million in revenue recognized from the LymphoStat-B agreement with GlaxoSmithKline (GSK). The Company reported a net loss of $67.3 million ($0.50 per share) for the quarter ended September 30, 2007, compared with a net loss for the third quarter of 2006 of $60.8 million ($0.46 per share).

For the first nine months of 2007, HGS reported increased revenues of $29.3 million compared with revenues of $15.7 million for the same period of the previous year. Revenues for the first nine months included $19.2 million in revenue recognized from the Albuferon agreement with Novartis and $4.9 million in revenue recognized from the LymphoStat-B agreement with GSK. The Company reported a net loss of $169.6 million ($1.26 per share) for the nine months ended September 30, 2007, compared with a net loss of $184.2 million ($1.40 per share) for the same period of the previous year.

As of September 30, 2007, cash and investments totaled $688.8 million, of which $620.0 million is unrestricted and available for operations. This compares with cash and investments totaling $763.1 million, of which $701.9 million was unrestricted and available for operations, as of December 31, 2006.

HIGHLIGHTS OF RECENT PROGRESS

Albuferon: Enrollment of Phase 3 Trials Completed Two Months Ahead of Schedule

In a separate press release issued this morning, HGS announced that it has completed enrollment two months ahead of schedule in ACHIEVE 2/3, the second of two pivotal Phase 3 trials of Albuferon (albinterferon alfa-2b) in
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Human Primary Preadipocytes and Differentiated Adipocytes
2. Low Abundance cDNA Cloned Using Stratagenes Human Universal cDNA Library
3. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Human Universal cDNA Library Array I
6. Map and Link Human Genetic Disorders with SSLP Analysis
7. RT-PCR Primer Sets for Human and Mouse Mismatch Repair Genes
8. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
9. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
10. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
11. Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression Vector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Pacific Northwest Biotechnology, LLC ... Global Markets Direct,s, ,Pacific Northwest Biotechnology, LLC ... overview of the Pacific Northwest Biotechnology, LLC,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... analysis at various stages, therapeutics assessment by drug ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... September 30, 2014 Genedata, ... for drug discovery and related life science ... has chosen Genedata Selector as its host-pathogen ... data. FUNGITECT is a European consortium dedicated ... diseases via individualized anti-fungal drug therapies. Genedata ...
(Date:9/30/2014)... iLab Solutions announced the results of its ... focuses on core facility operations, growth and utilization as ... , In its 4th year running, a number of ... year-over-year decrease in the percentage of revenue that comes ... the constraints of this trend. When asked, “What are ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3
(Date:9/30/2014)... captured the popular attention of both children and aquarium ... sold as dehydrated eggs, these tiny brine shrimp readily ... tank of salt water. , Physicists, though, are ... shrimp vertically migrate in large groups in response to ... night and retreating deeper during the day. , Two ...
(Date:9/30/2014)... Ecker, a Salk professor and Howard Hughes Medical ... have been named recipients in the 2014 round ... (NIH) through the BRAIN (Brain Research through Advancing ... The grant, announced September 30, provides more than ... over three years. , The BRAIN Initiative, launched ...
(Date:9/30/2014)... tetrachloroethylene (PCE) in drinking water may increase the ... a new study led by a Boston University ... published in the journal Environmental Health , ... among 1,766 women in Cape Cod, Ma., where ... the early 1980s by the installation of vinyl-lined ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Salk scientists receive $3 million for BRAIN Initiative grant 2Contaminated water linked to pregnancy complications, BU study finds 2
... company spun off by The Children,s Hospital of Philadelphia, ... innovative drug delivery system using magnetically targeted nanoparticles to ... West Philadelphia, announced that Devon Park Bioventures, of Wayne, ... financing agreement. "It,s exciting to see that one ...
... tuberculosis can cause tuberculosis with as little as 10 ... to tens of millions of cells to cause cholera? This ... Institute, in France, and the Instituto Gulbenkian de Ciencia and ... issue of the journal PLoS Pathogens . The researchers ...
... The 9th annual Seena Magowitz Celebrity Golf Classic raised ... Research Institute (TGen) through the Seena Magowitz Foundation. ... run by TGen,s Pancreatic Cancer Research Team. This ... suppliers in the mattress industry longtime supporters of ...
Cached Biology News:Biotech firm spun off from Children's Hospital raises $7 million to advance vascular treatment 2Frontal attack or stealth? 2Celebrity Golf Classic raises $553,443 for Seena Magowitz Foundation 2
TRBP1 Antibody...
Complete cell culture media with cytokines...
Complete cell culture media with cytokines...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Biology Products: